Comparison of Efficacy And Safety of Albumin Paclitaxel Combined with Gemcitabine And S-1 Combined with Gemcitabine in the Treatment of Metastatic Pancreatic Cancer
Objective:To compare and analyze the clinical efficacy and safety of albumin paclitaxel combined with gemcit-abine and S-1 combined with gemcitabine in the treatment of metastatic pancreatic cancer.Methods:Seventy-five patients with metastatic pancreatic cancer diagnosed in Hunan Cancer Hospital from January 2021 to January 2024 were divided into two groups according to the treatment Methods:the treatment group of albumin paclitaxel combined with gemcitabine was AG group,with 38 cases in total;The treatment group of S-1 combined with gemcitabine was GS group,with 37 cases in total.The therapeutic effects and adverse reactions of the two groups were compared.Results:Both groups completed at least 2 cycles of chemotherapy.The ORR of chemotherapy in AG group was 15.8%,and the DCR was 50.0%.The ORR and DCR of chemotherapy in GS group were 7.4%and 18.5%respectively.Comparison of ORR of chemotherapy between the two groups,P>0.05;However,the DCR of the two groups was significantly higher in AG group than in GS group,P<0.05.The incidence of bone marrow suppression in GS group Ⅰ～Ⅱ was 67.6%,and that in AG group was 76.3%,P>0.05.The incidence of digestive tract reaction in GS group was 100%,and that in AG group was 100%,compared with each other,P>0.05.There was no chemotherapy-related death in both groups,P>0.05.Conclusion:Gemcitabine com-bined with albumin paclitaxel in the treatment of metastatic pancreatic cancer is significantly better than gemcitabine com-bined with S-1 in disease control,and the adverse reactions have not increased significantly.
国家科技期刊平台
NSTL
万方数据
